

✓JTO & JTO CRR are the official journals of @IASLC & the source for information on detection, prevention, diagnosis & treatment of thoracic cancers. jtocrr.org


🔥PECATI final analysis: lenvatinib + pembrolizumab in pretreated B3 thymoma & thymic carcinoma 🆙 @JTOonline ☑Phase 2; N=43 (84% TC); mFU 24.6 mo 🎯mPFS 22.1 mo, mOS 40.2 mo; 36-mo OS 53.0%; ORR 25.6% 🎯Grade ≥3 TRAEs 44.2% (discontinuation 27.9%); grade 3 irAEs 11.6% 🎙 @JordiRemon @nicogirardcurie @NReguart @BenjaminBesseMD #LCSM @OncoAlert @Larvol jto.org/article/S1556-0864(2…

Celebrating a leader who has helped support scientific discovery and knowledge sharing for nine years. Thank you, Johan Vansteenkiste! #JTO20

As we reflect on two decades of JTO, we're grateful for contributors like Ramon Rami-Porta, whose seven years of service have left a lasting mark. #JTO20

What’s next for patients with platinum-refractory advanced B3 thymoma and thymic carcinoma? With no standard second-line treatment, new research is critical. Remon et al. share updated findings from the PECATI trial, now published in #JTO. Read more: bit.ly/3Xqcqra

One of my final research projects from fellowship! We examined real-world adoption of first-line immunotherapy in advanced NSCLC over the past decade, finding substantial increases in uptake but persistent disparities across patient populations. Thank you @JTOonline for highlighting our work, and grateful to all my coauthors and collaborators!

#LDCT lung cancer screening has been an approved covered benefit for adults aged 55-77 years by the Centers for Medicare and Medicaid Services since 2015. Miller et al. sought to compare the cancer detection rates in a general population #lungcancer screening registry to the #NLST, which they found were comparable. Read the article here: bit.ly/4sObSaB #LungCancerResearch #JTO

Stay tuned for the upcoming Nov JTO Insights podcast on this article! @JTOonline @DrAlexAdjei

📊 JTO Fun Fact Looking for the latest on TNM staging? JTO curates IASLC Staging Articles, including proposals for the Ninth Edition of TNM Stage Classification of Thoracic Tumors. Access the collection: bit.ly/4gwWMlg #JTO20 #GlobalOncology

Join us in recognizing Tetsuya Mitsudomi for nine years of service and his contributions to JTO's continued success! #JTO20

Phase II results for soxataltinib, CNS penetrant selective RET inhibitor, in NSCLC @JTOonline. As 1L therapy, RR 89.3%, TTR 0.9m, PFS 19.3m, intracranial RR 100% (n=4) and TRAEs included AST elevation (71%, G3+ 9%) and notably, diarrhea (79%, G3+ 18%). jto.org/article/S1556-0864(2…

Amid ongoing debate about the optimal technical strategy of performing ctDNA-based assays to detect minimal residual disease after surgery, Cui et al. put the methods to the test. In 417 plasma samples from 84 patients with stages I-III LC, they found that personalized tumor-informed assays provided the best prediction for disease recurrence. Dive into the details here: bit.ly/4swRBpR #ctDNA #LungCancer #LungCancerResearch #JTO

Thank you to Graham Warren for ten years of helping JTO serve as a trusted resource for the global thoracic oncology community! #JTO20

Patients with pulmonary carcinoid have a well-differentiated, though rare, tumor. But not much is known about the disease’s response to DLL3-targeted bispecific T-cell engager #tarlatamab. @JessieStuart316 et al. analyzed the response in 11 patients at Memorial Sloan Kettering Cancer Center and found that #tarlatamab is a promising treatment option for patients with PC. Read more here: bit.ly/4suaCsN #LungCancerResearch #JTO

#LCAM26: #JTO Editor-in-Chief @DrAlexAdjei shares his thoughts in the editorial "The Price of Progress in Lung Cancer: Global Disparities, Drug Costs, and the Challenge of Equitable Access" 🆓 access: jto.org/article/S1556-0864(2… @JTOonline @IASLC #LCAM @ElsevierConnect

New data from @YaleThoracic shows patients with #NSCLC receiving neoadjuvant immune checkpoint inhibitors plus chemotherapy (ICI-CT) have improved survival - with excellent survival in patients with major pathological response (MPR) vs. those without. jtocrr.org/article/S2666-364… @SmilowCancer @GavittWoodard @Sokim_33 @yalepathology @JTOonline